Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07070466 · ClinicalTrials.gov registry record · Phase 2
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
A Phase 2 study of Stomach Cancer and Esophagus Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT07070466: Recruiting Phase 2 study of Stomach Cancer and Esophagus Cancer, sponsored by Massachusetts General Hospital.
NCT07070466 is a Phase 2 study of Stomach Cancer and Esophagus Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 633-participant average among 15 other Stomach Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07070466, a Phase 2 study of Stomach Cancer and Esophagus Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
Primary Outcome
The primary endpoint is to estimate the 6-month progression free survival rate for the combination of ivonescimab in combination with FOLFOX in frontline GEA adenocarcinomas. Progression is defined as measured from the start of the treatment with ivonescimab to the date of either documentation of disease progression or death. Progression of disease is defined per RECIST 1.1 criteria.
Conditions Studied
Interventions
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Ivonescimab
- DRUG 5-Fluorouracil
Study Locations (2)
California
- UCLA - Santa Monica
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-10-10 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 2 |
What NCT07070466 shows while recruiting
NCT07070466 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 633-participant average among 15 other Stomach Cancer trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Stomach Cancer appearing as the primary indexed condition, and to 4 interventions - of which Leucovorin is the first listed.
NCT07070466 reports a single indexed study location in California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07070466 about?
NCT07070466 is a clinical study titled "Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA". This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
What is the current status of trial NCT07070466?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-10-10. Estimated completion is 2028-09-01.
What conditions does trial NCT07070466 study?
This clinical trial studies the following conditions: Stomach Cancer, Esophagus Cancer, Stomach Cancer Stage IV.
What interventions are being tested in trial NCT07070466?
The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), Ivonescimab (DRUG), 5-Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT07070466?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07070466 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stomach Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07070466's enrollment target sits among peer trials
40 9th of 15 higher than 5 of 15 other Stomach Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stomach Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Avutometinib and Defactinib in Diffuse Gastric Cancer
RECRUITING · Phase 2
-
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
COMPLETED · Phase 2
-
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
COMPLETED · Phase 2
-
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
COMPLETED · Phase 2
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI